Hints and tips:
Related Special Reports
...Other drugmakers could still “win” the race in the rapidly growing obesity market dominated by Novo Nordisk and Eli Lilly, according to the chief executive of biotech company Zealand Pharma....
...“All it takes is one large company like Eli Lilly to do it and then more risk-averse companies follow suit,” he said....
...Eli Lilly and Vertex declined to comment on the talks....
...But the companies do not have a history of protein manufacturing used by Novo Nordisk and its US rival Eli Lilly to make their diabetes and weight-loss products....
...Eli Lilly’s chief executive David Ricks attributed the drugmaker’s performance to “strong sales of Mounjaro and Zepbound”, and said the company was “rapidly expanding manufacturing capacity to make our incretin...
...Eli Lilly said that it plans to submit the results to the US Food and Drug Administration and other medicine regulators worldwide to seek approval for tirzepatide as a sleep apnoea treatment beginning this...
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against US pharmacy chains such as CVS and Walgreens. Read more here...
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against pharmacies such as CVS and Walgreens....
...A decision from the US Food and Drug Administration on Eli Lilly’s donanemab drug was originally due by the end of the first quarter but the breakthrough medicine will now be subject to a further review...
...Dear reader, It isn’t often that a company pays good money to criticise customers for buying its product. But that is what Eli Lilly did this week....
...BSP previously produced Covid antibody treatment bamlanivimab for Eli Lilly....
...Demand for a new class of diabetes and obesity drugs will boost US drugmaker Eli Lilly’s sales by 20 per cent in 2024, pushing its revenues above $40bn, the company said on Tuesday....
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
...Amazon Pharmacy stands to generate “a lot of revenue” from drugs such as Eli Lilly’s Zepbound injection and Novo Nordisk’s Wegovy, which are both available to patients directly through the Amazon website...
...Eli Lilly has called for competition regulators to scrutinise an $11bn deal by its main competitor Novo Nordisk to snap up additional manufacturing capacity, as the rivalry between the drugmakers to dominate...
...Mounjaro will become available “within weeks” in Great Britain for treatment of both diabetes and obesity, after the medicines regulator authorised US pharma company Eli Lilly on Thursday to sell the weight...
...Developed respectively by Novo Nordisk and Eli Lilly, they are now being prescribed to millions of people....
...US biotech Viking Therapeutics’ shares more than doubled after trial data for the company’s weight-loss drug outperformed existing treatments from drugmakers Novo Nordisk and Eli Lilly....
...The US federal drug regulator has approved Eli Lilly’s injectable diabetes medication for weight loss, as demand for the blockbuster treatments continues to surge....
...Eli Lilly lowered its expectations for full-year earnings because of accounting charges related to recent acquisitions, despite beating expectations in the third quarter driven by growth in diabetes and...
...Highlighting continued caution from regulators, the agency last month delayed an approval decision on donanemab, Eli Lilly’s Alzheimer’s drug....
...Meanwhile Novo Nordisk has faced competition from rivals including Eli Lilly, the maker of Mounjaro and Zepbound drugs, which reported strong sales growth on Wednesday....
...The side effects of Eli Lilly’s and Novo Nordisk’s obesity treatments are very similar, and patients could switch from one to the other, Stanford said....
...Indianapolis-based Eli Lilly, meanwhile, has become the world’s largest pharmaceutical company on the back of sales of its drug Mounjaro for diabetes and strong trial results for its use in weight loss....
...They include the popular new diabetes and weight-loss drugs Ozempic and Wegovy, made by Novo Nordisk, and Mounjaro and Zepbound made by Eli Lilly....
International Edition